跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 31,669 条关于
“UBS Asset Management Singapore”
全部
31,669
临床试验
20,305
药物
426
机构
436
资讯
10,502
3个月前
AI-Powered Cellular Reprogramming Attracts Major Investment as Biotech Firms Target US$610 Billion Longevity Market
6个月前
METiS TechBio Debuts on Hong Kong Exchange as World's First Publicly Listed AI-Powered Drug Delivery Company
去年
Acelyrin's Izokibep Advances in Phase 3 Trials Amidst Analyst Revisions and Institutional Investment
去年
Singapore Trial to Evaluate Multicomponent Intervention for Chronic Kidney Disease Management
2年前
NImmune Biopharma to Present Omilancor Progress at UBS Symposium
16天前
UBS Lifts J&J Price Target to $320 on Oncology and Immunology Growth Outlook
去年
WuXi Companies Consider Asset Sales Amid US BIOSECURE Act Pressure
去年
WuXi XDC Completes Singapore Manufacturing Facility, Expanding Global Bioconjugate Production Network
去年
Norstella Launches NorstellaLinQ, an Integrated Data Asset for Biopharma
去年
Orthocell's Remplir Receives Regulatory Approval in Singapore
第 1 页，共 1051 页
上一页
下一页
